Please use this identifier to cite or link to this item:
Title: Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study)
Author: Hernández Rojas, Zojaina
Dalmau Llorca, Maria Rosa
Aguilar Martín, Carina
Gonçalves, Alessandra Queiroga
Casajuana, Marc
Fernández Sáez, José
Rodríguez Cumplido, Dolores
Forcadell Drago, Emma
Carrasco Querol, Noèlia
Pepió Vilaubí, Josep Maria
Alegret, Josep M.
Keywords: Cost de l'assistència sanitària
Assaigs clinics
Anticoagulants (Medicina)
Vitamines K
Cost of medical care
Clinical trials
Anticoagulants (Medicine)
Vitamin K
Issue Date: 4-Sep-2020
Publisher: Ovid Technologies (Wolters Kluwer Health)
Abstract: Background: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischaemic stroke in patients with nonvalvular atrial fibrillation, including all the active ingredients marketed in Spain, prescribed for 2 years in the Primary Care service of the Institut Català de la Salut. Methods: Population-based cohort study, in which the cost of the 2 treatment groups will be evaluated. Direct costs (pharmacy, primary care, emergency and hospitalization) and indirect costs (lost productivity) will be included from a social perspective. Effectiveness (assessed as the occurrence of a health event, the 1 of primary interest being stroke) will be determined, with a 2-year time horizon and a 3% discount rate. The average cost of the 2 groups of drugs will be compared using a regression model to determine the factors with the greatest influence on determining costs. We will carry out a univariate ('one-way') deterministic sensitivity analysis. Discussion: We hope to provide relevant information about direct and indirect costs of oral anticoagulants, which, together with aspects of effectiveness and safety, could help shape the consensual decision-making of evaluating bodies.
Note: Reproducció del document publicat a:
It is part of: Medicine, 2020, vol. 99 (36), num. e22054
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Cost_effectiveness_of_direct_oral_anticoagulants.79.pdf281.63 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons